Document Type
Article
Department
Internal Medicine (East Africa)
Abstract
Acute pancreatitis is a condition seldom encountered with the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors. They are beneficial in the treatment of various conditions and offer great promise. Despite this, they are associated with several adverse effects, necessitating vigilance and further research. This case study reports a 69-year-old male with multiple comorbidities who presented with epigastric pain radiating to the back. Laboratory tests revealed elevated AST, ALT, GGT and lipase. The patient was diagnosed with acute pancreatitis secondary to the SGLT2 inhibitor therapy regimen. Cessation of dapagliflozin resulted in a complete resolution of symptoms. There is credible evidence to suggest the presence of an association between SGLT2 inhibitors and acute pancreatitis, although extensive research is warranted to consolidate this association.
Publication (Name of Journal)
Cureus
DOI
doi:10.7759/cureus.62957
Recommended Citation
Khakhar, Z.,
Manji, S.,
Patel, R.,
Karar, S.
(2024). Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors and the risk of pancreatitis: A case report. Cureus, 16(6), 1-5.
Available at:
https://ecommons.aku.edu/eastafrica_fhs_mc_intern_med/420
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Included in
Endocrinology, Diabetes, and Metabolism Commons, Family Medicine Commons, Internal Medicine Commons